BIOR News and Press, Biora Therapeutics Inc. From 11/13/23

2023-11-13 21:04:02 ET Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Conference Call November 13, 2023, 16:30 ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis...

2023-11-13 16:12:02 ET More on Biora Therapeutics Biora submits updated IND application to FDA for BT-600 Biora IND for BT-600 delayed due to FDA request for more info Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Bior...

NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Managem...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Biora Therapeutics Inc. (BIOR) is expected to report $-0.93 for Q3 2023

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023.   The ...

2023-10-30 17:37:32 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript Biora IND for BT-600 delayed due to FDA request for more info Biora Therapeutics reduces debt by $50M, largest shareholder increases equity exposure ...

Update includes supplemental information and provides additional time to complete regulatory review Biora anticipates remaining on track with its phase 1 clinical trial execution timeline SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), th...

2023-10-23 18:48:57 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript Biora Therapeutics reduces debt by $50M, largest shareholder increases equity exposure Biora gains after update on drug delivery device Seeking ...

Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Update to include supplemental information and allow additional time to complete regulatory review SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the...